Related references
Note: Only part of the references are listed.Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study
Kaj Stenlof et al.
CURRENT MEDICAL RESEARCH AND OPINION (2014)
Optimal back-extrapolation method for estimating plasma volume in humans using the indocyanine green dilution method
David Polidori et al.
THEORETICAL BIOLOGY AND MEDICAL MODELLING (2014)
Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A 52-week randomized trial
Guntram Schernthaner et al.
DIABETES CARE (2013)
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
H. J. Lambers Heerspink et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
J-F Yale et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
K. Stenlof et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
F. J. Lavalle-Gonzalez et al.
DIABETOLOGIA (2013)
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
J. P. H. Wilding et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2013)
Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus
David Polidori et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus
Damayanthi Devineni et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
William T. Cefalu et al.
LANCET (2013)
Achievement of Goals in U.S. Diabetes Care, 1999-2010
Mohammed K. Ali et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter Inhibitor, as Add-On to Meiformin in Subjects With Type 2 Diabetes
Julio Rosenstock et al.
DIABETES CARE (2012)
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Silvio E. Inzucchi et al.
DIABETES CARE (2012)
Obesity 3 Quantification of the effect of energy imbalance on bodyweight
Kevin D. Hall et al.
LANCET (2011)
Body Fluid Volumes and the Response of Renin and Aldosterone to Short- and Long-Term Thiazide Therapy of Essential Hypertension
P. Brummelen et al.
ACTA MEDICA SCANDINAVICA (2010)
From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus
Harold Bays
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications
George L. Bakris et al.
KIDNEY INTERNATIONAL (2009)
Impact of the time window on plasma volume measurement with indocyanine green
M. Jacob et al.
PHYSIOLOGICAL MEASUREMENT (2008)
SLC2A9 Is a High-Capacity Urate Transporter in Humans
Mark J. Caulfield et al.
PLOS MEDICINE (2008)
Technical and physiological background of plasma volume measurement with indocyanine green: a clarification of misunderstandings
Matthias Jacob et al.
JOURNAL OF APPLIED PHYSIOLOGY (2007)
Determination of plasma volume by indocyanine green - validation of the method and use in patients after cardiopulmonary bypass
SE Menth-Meier et al.
INTENSIVE CARE MEDICINE (2001)
Share Paper
